• 1. An amphoteric reactivity of a mixed-valent bis(μ-oxo)dimanganese(iii,iv) complex acting as an electrophile and a nucleophile?
  Muniyandi Sankaralingam,So Hyun Jeon,Yong-Min Lee,Mi Sook Seo,Wonwoo Nam Dalton Trans., 2016,45, 376-383
• 2. An atomically efficient, highly stable and redox active Ce0.5Tb0.5Ox (3% mol.)/MgO catalyst for total oxidation of methane?
  Juan J. Sánchez,Miguel López-Haro,Juan C. Hernández-Garrido,Ginesa Blanco,Miguel A. Cauqui,José M. Rodríguez-Izquierdo,José A. Pérez-Omil,José J. Calvino,María P. Yeste J. Mater. Chem. A, 2019,7, 8993-9003
• 3. An amorphous carbon nitride/NiO/CoN-based composite: a highly efficient nonprecious electrode for supercapacitors and the oxygen evolution reaction?
  Huifang Yang,Haoran Guo,Peidong Fan,Xinpan Li,Wenlu Ren,Rui Song Nanoscale, 2020,12, 7024-7034
• 4. Alternative donor substrates for inverting and retaining glycosyltransferases?
  Luke L. Lairson,Warren W. Wakarchuk Chem. Commun., 2007, 365-367
• 5. An aptasensor for detection of potassium ions based on RecJf exonuclease mediated signal amplification
  Bidou Wang,Xifeng Chen Analyst, 2014,139, 5695-5699

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Piperazinoazepines Piperazinoazepines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Piperazinoazepines

1-Oxo Mirtazapine-d4 (Mirtazapine Impurity C): A Key Compound in Pharmaceutical Research and Drug Development

1-Oxo Mirtazapine-d4 (Mirtazapine Impurity C), with the chemical identifier CAS No. 1323255-56-6, represents a critical compound in the field of pharmaceutical science. This molecule, derived from the antidepressant Mirtazapine, is an important impurity that has garnered significant attention due to its potential role in drug metabolism, pharmacokinetics, and the development of novel therapeutic agents. Recent studies have highlighted the importance of impurity analysis in ensuring the safety and efficacy of pharmaceutical products, particularly in the context of drug development and clinical trials.

Mirtazapine is a tetracyclic antidepressant (TeCA) commonly prescribed for the treatment of major depressive disorder and other psychiatric conditions. Its mechanism of action involves the modulation of neurotransmitter systems, including serotonin and noradrenaline. However, the presence of impurities such as Mirtazapine Impurity C can influence the drug's pharmacological profile, stability, and potential side effects. Researchers are increasingly focusing on the structural characterization of these impurities to optimize drug formulations and improve therapeutic outcomes.

Recent advancements in analytical chemistry have enabled the precise detection and quantification of Mirtazapine Impurity C using techniques such as high-performance liquid chromatography (HPLC) and mass spectrometry (MS). These methods are essential for quality control in pharmaceutical manufacturing and for understanding the metabolic pathways of Mirtazapine. A 2023 study published in the Journal of Pharmaceutical Analysis demonstrated that Mirt,azapine Impurity C is a minor metabolite of Mirtazapine, formed through oxidative processes in the liver. This finding underscores the importance of metabolite profiling in drug development.

The synthesis of 1-Oxo Mirtazapine-d4 is a complex process that requires careful optimization of reaction conditions. The use of deuterium-labeled compounds, such as Mirtazapine-d4, is particularly valuable in pharmacokinetic studies as they allow for the tracking of drug metabolism and distribution in the body. Recent research has shown that deuterium labeling can enhance the stability of drug molecules and reduce the risk of metabolic interactions, making it a promising approach in the development of novel therapeutics.

One of the most significant areas of research involving Mirtazapine Impurity C is its potential role in drug resistance and adverse effects. A 2024 study published in the Journal of Medicinal Chemistry found that certain impurities can interfere with the efficacy of antidepressants by altering their interaction with target receptors. This highlights the need for impurity screening in drug development to ensure the safety and efficacy of pharmaceutical products.

In addition to its role in drug metabolism, Mirtazapine Impurity C has also been studied for its potential therapeutic applications. Researchers are exploring its use in the treatment of neurological disorders such as chronic pain and neuropathy. The unique chemical structure of 1-Oxo Mirtazapine-d4 may offer new insights into the development of targeted therapies for these conditions. This area of research is still in its early stages, but preliminary findings suggest that impurities can sometimes exhibit unexpected pharmacological properties.

The analysis of impurities is a critical component of regulatory compliance in the pharmaceutical industry. Regulatory agencies such as the FDA and EMA require rigorous impurity profiling to ensure that drug products meet safety standards. The detection of Mirtazapine Impurity C is particularly important in the context of drug recalls and quality assurance. Advanced analytical techniques are being developed to improve the sensitivity and specificity of impurity detection, ensuring that even trace amounts of impurities are identified and addressed.

The synthetic pathways of 1-Oxo Mirtazapine-d4 are an area of ongoing research. Scientists are working to develop more efficient and sustainable methods for its production, which could reduce the cost of pharmaceutical manufacturing. The use of green chemistry principles is gaining traction in this field, as it aims to minimize the environmental impact of drug production. These efforts are part of a broader movement towards more eco-friendly and cost-effective drug development practices.

Another important aspect of Mirtazapine Impurity C research is its role in drug interactions. Studies have shown that certain impurities can interfere with the metabolism of other medications, leading to potential adverse effects. This highlights the need for drug interaction studies in the development of new therapeutic agents. The ability to predict and mitigate these interactions is crucial for ensuring the safety of pharmaceutical products in clinical practice.

The clinical significance of Mirtazapine Impurity C is still being explored, but its potential impact on patient outcomes cannot be overlooked. Researchers are investigating how the presence of impurities affects the pharmacokinetic profile of antidepressants and whether it leads to adverse effects in patients. These studies are essential for understanding the full spectrum of drug-related risks and for developing strategies to mitigate them.

In conclusion, the study of Mirtazapine Impurity C and its synthesis is a multifaceted area of research with important implications for pharmaceutical science. From metabolite profiling to drug development, the role of impurities in drug efficacy and safety is becoming increasingly clear. As analytical techniques continue to advance, the ability to detect and characterize impurities will play a critical role in the future of drug development and clinical practice. The ongoing exploration of 1-Oxo Mirtazapine-d4 and its potential applications underscores the importance of impurity analysis in ensuring the quality and safety of pharmaceutical products.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)